MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

CURATE.AI Optimized Modulation for Multiple Myeloma

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2018-11-29
Last Posted Date
2023-09-06
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
20
Registration Number
NCT03759093
Locations
🇸🇬

National University Hospital, Singapore, Singapore

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

First Posted Date
2018-11-29
Last Posted Date
2025-01-08
Lead Sponsor
University of Rochester
Target Recruit Count
40
Registration Number
NCT03758989
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer

Not Applicable
Conditions
Breast Cancer
Breast Neoplasms
Breast Diseases
Interventions
First Posted Date
2018-11-28
Last Posted Date
2018-12-07
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
100
Registration Number
NCT03756090

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

First Posted Date
2018-11-28
Last Posted Date
2024-04-04
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
250
Registration Number
NCT03755804
Locations
🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

🇺🇸

St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Phase 1
Completed
Conditions
Triple Negative Breast Cancer
Interventions
Drug: GX-I7
Drug: Pembrolizumab(KEYTRUDA®)
Drug: Cyclophosphamide
First Posted Date
2018-11-26
Last Posted Date
2024-03-05
Lead Sponsor
Genexine, Inc.
Target Recruit Count
84
Registration Number
NCT03752723
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of

🇰🇷

Gangnam Severance Hospital, Seoul, Korea, Republic of

and more 9 locations

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2
Active, not recruiting
Conditions
Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma, Not Otherwise Specified
Indolent Non-Hodgkin Lymphoma
Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Aggressive Non-Hodgkin Lymphoma
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Interventions
First Posted Date
2018-11-21
Last Posted Date
2024-11-04
Lead Sponsor
David Bond, MD
Target Recruit Count
30
Registration Number
NCT03749018
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

Phase 1
Conditions
Metastatic Breast Cancer
Breast Cancer
Breast Neoplasms
Stage IV Breast Cancer
Metastatic Cancer
Invasive Ductal Carcinoma of Female Breast
Invasive Ductal Breast Cancer
Adenocarcinoma Breast
Interventions
Drug: LTLD
Procedure: MR-HIFU induced hyperthermia
Drug: Cyclophosphamide
First Posted Date
2018-11-21
Last Posted Date
2021-02-17
Lead Sponsor
UMC Utrecht
Target Recruit Count
12
Registration Number
NCT03749850
Locations
🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1
Recruiting
Conditions
Rectal Cancer
Colon Cancer
Gastric Cancer
Gastrointestinal Cancer
Pancreatic Cancer
Interventions
First Posted Date
2018-11-19
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT03745326
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1
Terminated
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Interventions
Drug: JCAR017
Drug: Lymphodepleting
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2018-11-16
Last Posted Date
2024-08-15
Lead Sponsor
Celgene
Target Recruit Count
21
Registration Number
NCT03743246
Locations
🇺🇸

Local Institution - 167, Redwood City, California, United States

🇺🇸

Local Institution - 161, Seattle, Washington, United States

🇺🇸

Local Institution - 165, Houston, Texas, United States

and more 16 locations

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Phase 1
Conditions
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
High Grade B-Cell Lymphoma, Not Otherwise Specified
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Interventions
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Biological: Rituximab
Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Drug: Vincristine Sulfate
First Posted Date
2018-11-15
Last Posted Date
2021-05-06
Lead Sponsor
Northwestern University
Target Recruit Count
12
Registration Number
NCT03742258
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath